Primary endpoint for Summit's drug in comparative US study by mid-2025? | Categorical | | | 7 months ago | |
FDA approval for Summit's cancer drug by end of 2024? | Binary | | | 7 months ago | |
Summit Therapeutics' drug achieves $1 billion in sales by end of 2025? | Binary | | | 7 months ago | |
Next steps for Summit's cancer drug in the US market by end of 2024? | Categorical | | | 7 months ago | |
Summit's partnerships for global distribution by end of 2024? | Categorical | | | 7 months ago | |
Will Summit's lung cancer drug outperform Keytruda in a US-based trial by end of 2024? | Binary | | | 7 months ago | |
What will be Summit's revenue from their lung cancer drug by end of 2024? | Categorical | | | 7 months ago | |
Will Summit's lung cancer drug receive FDA approval by end of 2024? | Binary | | | 7 months ago | |
Will Summit's market cap exceed 10 billion USD by end of 2024? | Binary | | | 7 months ago | |
How will Summit's share price perform by end of 2024? | Categorical | | | 7 months ago | |
In which markets will Summit's lung cancer drug receive approval by end of 2024? | Categorical | | | 7 months ago | |
Summit Therapeutics' market cap exceeds $10 billion by mid-2024? | Binary | | | 7 months ago | |
Summit Therapeutics' stock price at end of 2024? | Categorical | | | 7 months ago | |
Next key regulatory milestone for Ivonescimab by end of 2024? | Categorical | | | 7 months ago | |
Summit Therapeutics submits FDA approval application for Ivonescimab by 2024? | Binary | | | 7 months ago | |
Ivonescimab receives FDA approval by mid-2025? | Binary | | | 7 months ago | |
Summit Therapeutics' next step for Ivonescimab by end of 2024? | Categorical | | | 7 months ago | |
Company with highest stock increase in 2024 following Ivonescimab news? | Categorical | | | 7 months ago | |
Ivonescimab FDA approval for NSCLC by end of 2024? | Binary | | | 7 months ago | |
Summit Therapeutics stock price above $10 by August 31, 2024? | Binary | | | 7 months ago | |
Next milestone for Ivonescimab by end of 2024? | Categorical | | | 7 months ago | |
Will Summit Therapeutics' stock price reach $30 per share by the end of 2024? | Binary | | | 3 months ago | |
Will Summit Therapeutics' market cap reach $25 billion by mid-2024? | Binary | | | 3 months ago | |
Summit Therapeutics' market cap reaches $10 billion by mid-2025? | Binary | | | 7 months ago | |
Peak market cap of Summit Therapeutics in 2024? | Categorical | | | 7 months ago | |
Merck files legal challenge against Summit Therapeutics by end of 2024? | Binary | | | 7 months ago | |
What will Summit Therapeutics' market cap be at the end of 2024? | Categorical | | | 3 months ago | |
Will ivonescimab achieve sales exceeding $500 million by end of 2025? | Binary | | | 4 months ago | |
Will Summit Therapeutics' stock price increase by 20% or more by December 31, 2024? | Binary | | | 4 months ago | |
Will Summit Therapeutics announce a partnership or acquisition by March 31, 2025? | Binary | | | 4 months ago | |
What will be Summit Therapeutics' revenue from ivonescimab by December 31, 2024? | Categorical | | | 4 months ago | |
What will Summit Therapeutics' stock price be at the end of Q1 2024? | Categorical | | | 3 months ago | |
Will Summit Therapeutics announce a new major partnership or acquisition by Q1 2024? | Binary | | | 3 months ago | |
What will Summit Therapeutics' next quarterly revenue report show? | Categorical | | | 3 months ago | |
Will ivonescimab receive FDA approval for PD-L1 positive advanced NSCLC by end of 2024? | Binary | | | 4 months ago | |
Will Merck announce a new trial or study in response to Ivonescimab's results by March 31, 2025? | Binary | | | 4 months ago | |
What will be the objective response rate (ORR) of ivonescimab in a follow-up trial by end of 2025? | Categorical | | | 4 months ago | |
Which company will be the next major competitor to release a new treatment for PD-L1 positive advanced NSCLC by end of 2025? | Categorical | | | 4 months ago | |
What will be the market share of ivonescimab compared to Keytruda in treating PD-L1 positive advanced NSCLC by end of 2025? | Categorical | | | 4 months ago | |
What will be the adoption rate of ivonescimab in NSCLC treatment by June 30, 2025? | Categorical | | | 4 months ago | |
Which lung cancer therapy will have the largest market share by December 31, 2025? | Categorical | | | 4 months ago | |
Will the FDA approve Summit Therapeutics' ivonescimab for NSCLC by December 31, 2024? | Binary | | | 4 months ago | |
